Selinexor

Selinexor (KPT-330), analog of KPT-185, is an orally bioavailable and selective CRM1 inhibitor[1][2].

Product Specifications

CAS Number

[1393477-72-9]

Product Name Alternative

KPT-330

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CRM1

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Selinexor.html

Purity

99.85

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NNC1=NC=CN=C1)/C=C\N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2

Molecular Formula

C17H11F6N7O

Molecular Weight

443.31

Precautions

H302, H315, H319, H335

References & Citations

[1]Etchin J, et al. KPT-330 inhibitor of CRM1 (XPO1) -mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013 Apr;161 (1) :117-27.|[2]Tai YT, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014 Jan;28 (1) :155-65.